|
Bolise Co. Limited Sektör : [ Tıbbi Malzeme ]
299 Hudong Rd Xiamen - - Çin
| bkherb bkherb | | | |
| 18965162351 | |
|
E-Mail
|
| | |
|
http://www.bkherb.com
|
|
Tıbbi Malzeme
Üretici
1990
10-50
2-5 Million US$
|
Son Güncelleme: 19.11.2018
Bu firmanın bilgilerini güncellemek ve değiştirmek istiyorsanız.Giriş
Bu bilgiler firmalar tarafından verilen bilgiler olup TurkeyBusiness.Com bu bilgilerin doğruluğu garanti etmez. Ayrıca bu bilgilerden dolayı sorumlu tutulamaz.
|
Tıbbi Malzeme sektöründeki firmaları görmek için ..
Tıbbi Malzeme sektör ürünleri görmek için
|
|
|
|
Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS NO.: 910463-68-2 Molecular Formula: C187H291N45O59 Molecular Weight: 4,113.64 Appearance:White Crystalline Powder Purity: 99.38% Identification: Infrared Absorption Loss On Drying: ≤0.2% Residue On Ignition: ≤0.3% Chloride:≤0.05% Sulfate:≤0.03% Heavy - metals:≤0.0015% Application: 1. Used as both injection-type or oral-type drug. 2. Used for the treatment of obesity. 3. Improve cardiovascular function 4. Treatment of type 2 diabetes in adults About Semaglutide: Semaglutide(Ozempic) is a glucagon-like peptide-1 analogue for once-weekly subcutaneous treatment of type 2 diabetes.Semaglutide is a pharmaceutical drug which is used for the treatment of type 2 diabetes. Semaglutide has demonstrated the potential to improve the treatment of type 2 diabetes and the positive recommendation from the Advisory Committee marks an important step towards making semaglutide available to adults with type 2 diabetes in the US. Semaglutide(Ozempic), a newly once-weekly glucagon like peptide-1 (GLP-1) receptor agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 diabetes mellitus (T2DM). In humans semaglutide is chemically similar to glucagon-like peptide-1 (GLP-1). Semaglutide is a glucagon-like peptide-1 (GLP-1) analog and functions as a GLP-1 agonist. Furthermore, semaglutide demonstrated a significant, beneficial effect on cardiovascular outcomes and a safety profile similar to that of other GLP-1 receptor agonists.Semaglutide also improves cardiovascular function, reduces the risk of stroke by 39%, and reduces the risk of myocardial infarction by 26%.
Semaglutide hakkında yapılan yorumlar |
Bu ürünle ilgili yorum yapılmamış
Semaglutide ile ilgili yorum yazınız
|
|
|